• ARCHIMED completed its previously announced acquisition of Standard BioTools’ microfluidics business, which will operate independently as Biomark Scientific.
• The genomics tools business will retain its existing team, maintaining continuity of products and services for customers.
• Under ARCHIMED, Biomark Scientific plans to expand its capabilities across genomics, clinical research and public health.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Standard BioTools Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030730PRIMZONEFULLFEED9868904) on November 03, 2026, and is solely responsible for the information contained therein.